Innovations are emerging in targeted therapies for solid tumors including trispecific T-cell engager EVOLVE-104 from Evolveimmune with FDA IND clearance, and new antibody-drug conjugates targeting anaplastic lymphoma kinase (ALK) cancers showing promising preclinical results. Additionally, clinical trials continue to explore shortened radiation for muscle invasive bladder cancer and combination treatments for non-muscle invasive bladder cancer, reflecting a dynamic landscape in oncology research and therapeutic development.